Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Loi S, Salgado R, Curigliano G, Romero Díaz R, Delaloge S, Rojas García C, Kok M, Saura C, Harbeck N, Mittendorf E, Yardley D, Suárez Zaizar A, Caminos F, Ungureanu A, Reinoso-Toledo J, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu J, Pusztai L, McArthur H. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nature Medicine 2025, 1-9. PMID: 39838118, DOI: 10.1038/s41591-024-03414-8.Peer-Reviewed Original ResearchPathological complete responseIncreased pCR ratePhase 3 trialNeoadjuvant chemotherapyBreast cancerER+/HER2- BCNivolumab armPCR rateAnti-programmed death 1 agentsDouble-blind phase 3 trialEndpoint of pathologic complete responseStromal tumor-infiltrating lymphocyte levelsProgrammed death-ligand 1 expressionEstrogen receptor-positive breast cancerLower pathologic complete responseTumor-infiltrating lymphocyte levelsRandomized phase 3 trialReceptor-positive breast cancerHigh riskLigand 1 expressionEstrogen receptor-positivePrimary breast cancerTaxane-based chemotherapyDense lymphocytic infiltrateT cell immunosurveillanceClinical Implications of Breast Cancer Intrinsic Subtypes
Rios-Hoyo A, Shan N, Karn P, Pusztai L. Clinical Implications of Breast Cancer Intrinsic Subtypes. Advances In Experimental Medicine And Biology 2025, 1464: 435-448. PMID: 39821037, DOI: 10.1007/978-3-031-70875-6_21.Peer-Reviewed Original ResearchConceptsBasal-like cancersBreast cancerDistant recurrenceLuminal cancersEndocrine therapyAdjuvant chemotherapyClinical behaviorOncotype DX recurrence scorePathologic complete response rateTreated with preoperative chemotherapyExcellent long-term survivalRisk of early recurrenceBasal-like breast cancerBreast cancer intrinsic subtypesHER2-enriched cancersImmunotherapy to chemotherapyLuminal A cancersComplete response rateImmune checkpoint inhibitorsEstrogen receptor-negativeHER2-targeted therapyEstrogen receptor-positiveLevel of immune infiltrationHER2 gene amplificationAdjuvant endocrine therapy